Guanfacine as a potential preventive therapy for chronic migraine: a mechanistic hypothesis

Background Despite the recent therapeutic advances, approximately one-third of patients with chronic migraine fail to achieve clinically meaningful benefit, and existing oral preventive therapies remain limited by tolerability and off-target effects. There is, therefore, a pressing need for new, well-tolerated, mechanistically distinct preventive treatments for chronic migraine. This hypothesis article evaluates the pharmacological and biological rationale supporting guanfacine as a potential preventive therapy for chronic migraine. Hypothesis We hypothesize that guanfacine, a selective α2A-adrenergic receptor agonist already approved for hypertension and attention-deficit/hyperactivity disorder, may have the potential to prevent chronic migraine through three biologically plausible convergent mechanisms: (1) potential presynaptic inhibition of calcium-dependent release of CGRP, glutamate, substance P, and other pro-nociceptive neuropeptides from trigeminal primary afferents; (2) potential attenuation of peripheral and central sensitization within the trigeminovascular system and the trigeminocervical complex; and (3) potential modulation of descending pain control pathways arising from the locus coeruleus and prefrontal cortex. This hypothesis is supported by evidence linking the ADRA2B gene to trigeminal nerve disorders, by recently published randomized controlled trial data demonstrating enhanced analgesia when guanfacine is added to lidocaine for trigeminal nerve blocks, and by the established analgesic activity of related α2-adrenergic agonists in neuropathic pain. However, it is important to note, direct evidence supporting these mechanisms in migraine treatment is lacking, and the proposed effects are largely based on biological plausibility derived from α2-adrenergic receptor pharmacology and experimental observations. Implications Guanfacine has a favorable safety profile and a unique pharmacological signature compared with currently available migraine preventives. Despite indirect evidence presented here, it warrants evaluation in randomized, placebo-controlled trials for chronic migraine prevention.